Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Study of cutaneous toxicity of cetuximab and correlation with radiologic response
2010-019837-85Phase 2Completed
- Sponsor
- CHU de Poitiers
- Start
- Apr 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of cetuximab in metastatic colorectal adenocarcinoma (mCRC), sponsored by CHU de Poitiers. Primary endpoint: Cutaneous inflammatory marker variation by radiologic response. Started Apr 2010; status: completed.
02
Drugs
cetuximab
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2010-019837-85.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019837-85.